Authors | P/M | No. of patients | Dose/fractions | LC | PFS/OS | |||||
---|---|---|---|---|---|---|---|---|---|---|
All | P | M | From CRC | P/M | CRC | P/M | CRC | |||
Oh et al. 2012 [45] | M | 57 | 33 | 24 | 7 | 50Gy/5f, 60Gy/5f, 60Gy/4f | 3-y: 94.5% | 3-y: 80.0% | 2-y DFS: 59.7% | Â |
Binkley et al. 2015 [40] | M | 77 | Â | Â | 26 | 25Gy/1f, 50Gy/4f | 1-y: 91.3%; 2-y: 83.8% | 1-y: 74.5%; 2-y: 57.8% | 2-y OS: 74.7%, | Â |
Agolli et al. 2016 [42] | M | Â | Â | Â | 44 | 23Gy/1f 30Gy/1f 45Gy/3f | Â | 1-y: 68.8%; 2-y: 60.2% 3-y: 54.2% | Â | 2-y OS: 67.7%; 3-y OS: 50.8% 2-y PFS: 20.3% |
Thibault et al. 2014 [44] | P/M | 254 | Â | Â | 45 | 48-60Gy/4-5f | 2-y: 96% (P) | 2-y: 76% | Â | Â |
Qiu et al. 2015 [43] | M | Â | Â | Â | 65 | 50Gy/5-10f | Â | 2-y: 30% | Â | 2-y OS 42.8% 2-y PFS 23.5% |
Kinj et al. 2016 [49] | M | Â | Â | Â | 53 | 60Gy/3f | Â | 1-y: 79.8% 2-y: 78.2% | Â | 1-y OS: 83.8%; 2-y OS: 69.3% |
Oskan et al. 2017 [50] | M | Â | Â | Â | 40 | 26-60Gy/1-8f | Â | Â | Â | 1-y OS: 84%; 2-y OS: 73% 5-y OS: 39% |
Pasqualetti et al. 2017 [54] | M | Â | Â | Â | 33 | 24-27Gy/1f 27-42Gy/3f | Â | Â | Â | Median PFS:13.4Â m |
Jung et al. 2015 [48] | M | Â | Â | Â | 50 | 40-60Gy/3-4f | Â | 1-y: 88.7% 3-y: 70.6% | Â | 3-y OS: 64% 3-y PFS: 24% |
Hamamoto et al. 2012 [46] | P/M | 144 | 128 | 31 | 14 | 48-60Gy/4-5f | 2-y: 87% (P); 2-y: 50% (M) | Â | Â | Â |
Baschnagel et al. 2013 [37] | M | 32 | 0 | 32 | 10 | 48-60Gy/4-5f | 1-y: 97%, 2-y: 92%, 3-y: 85% | 2-y: 80% | 1-y OS:83%, 2-y OS: 76%, 3-y OS-: 63% | Â |
Navarria et al. 2014 [52] | M | 76 | 0 | 76 | 29 | 48Gy/4f, 60Gy/8f, 60Gy/3f | 1-y: 95%, 3-y: 89%. | Recurrence in 3 of 29 patients (locally and distance) | 1-y OS: 84.1%, 3-y OS: 73% | Â |
Singh et al. 2014 [53] | M | 34 | 0 | 34 | 13 | 50Gy/5f | 1-y: 95%, 2-y: 88%, 3-y: 80%. | All 5 patients with local recurrences had CRC | Â | Â |
Kim et al. 2009 [27] | M | 13 | 0 | Â | 13 | 39-51Gy/3f | Â | 1-y; 76.9%, 2-y: 52.7%, 3-y: 52.7% | Â | 1-y OS: 100%, 2-y OS; 75.5%, 3-y OS: 64.7% |
Hof et al. 2007 [41] | M | 61 | 0 | 61 | 8 | 13-30Gy/1f | 1-y: 88.6%, 2-y: 73.7%, 3-y: 63.1% | 3-y: 0% | 1-y OS: 78.4%, 2-y OS: 65.1%, 3-y OS: 47.8% | Â |
Nagata et al. 2002 [47] | P/M | 40 | 31 | 9 | 4 | 40-48Gy/4f | 1-y: 100% (P); 2-y: 100% (P); | 2 mtastases from colon relapsed at 6, 7Â m | Â | Â |
Takeda et al. 2011 [39] | P/M | 162 | 113 | 34 | 15 | 50Gy/5f | 1-y: 97% (P), 1-y: 86% (M) 2-y: 93% (P), 2-y: 82% (M) | 1-y: 80%, 2-y: 72% | Â | Â |
Okunieff et al. 2006 [17] | M | 50 | 0 | 50 | Â | 50Gy/10f | 1-y: 83% | Had an unexpected number of local failures. | Â | Â |
Yamamoto et al. 2014 [56] | P/M | 201 | 164 | 37 | 29 | 45Gy/3f, 48Gy/4f, 60Gy/8f, 60Gy/15f | 3-y: 78%(P), 5-y: 72% (P) | 3-y: 26%, 5-y: 26% | 3-y OS: 60.9%, 5-y OS: 38.1% | Â |
Helou et al. 2017 [55] | M | 120 | Â | Â | Â | 48-52Gy/4-5f | Â | Â | Â | Â |